Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging

被引:24
|
作者
Charil, Arnaud [1 ]
Shcherbinin, Sergey [1 ]
Southekal, Sudeepti [5 ]
Devous, Michael D. [5 ]
Mintun, Mark [1 ,5 ]
Murray, Melissa E. [4 ]
Miller, Bradley B. [1 ]
Schwarz, Adam J. [1 ,2 ,3 ]
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA
[3] Indiana Univ, Dept Radiol & Imaging Sci, Indianapolis, IN 46204 USA
[4] Mayo Clin, Jacksonville, FL 32224 USA
[5] Avid Radiopharmaceut, Philadelphia, PA USA
关键词
Hippocampal sparing; limbic predominant; subtype; tau; NEUROPATHOLOGICALLY DEFINED SUBTYPES; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; ATROPHY; F-18-AV-1451; PATHOLOGY; RECOMMENDATIONS; PATTERNS;
D O I
10.3233/JAD-190264
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the relative number of tangle counts in these regions, have been proposed-hippocampal sparing (relative sparing of the hippocampus but high cortical load), limbic predominant (high hippocampal load but lower load in association cortices), and typical (balanced neurofibrillary tangles counts in the hippocampus and association cortices) AD-and shown to be associated with distinct antemortem clinical phenotypes. The ability to distinguish these AD subtypes from the more typical tau signature in vivo could have important implications for clinical research. Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50-92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied. By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo. 6/45 (13%) participants were identified as hippocampal sparing and 6/45 (13%) as limbic predominant AD subtypes. Hippocampal sparing participants were significantly younger than those assigned to the other two subtypes. Worse performance on delayed recall was associated with increased hippocampal tau signal, and worse performance on the trail making test B-A was associated with lower values of the hippocampus to cortex ratio. Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes.
引用
收藏
页码:1037 / 1048
页数:12
相关论文
共 50 条
  • [1] IN VIVO TAU IMAGING WITH PET IN ALZHEIMER'S DISEASE
    Villemagne, V. L.
    Furumoto, S.
    Fodero-Tavoletti, M.
    Mulligan, R.
    Young, K.
    Kudo, Y.
    Masters, C. L.
    Yanai, K.
    Rowe, C. C.
    Okamura, N.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 32 - 33
  • [2] Tau PET Imaging in Alzheimer's Disease
    Okamura, Nobuyuki
    Harada, Ryuichi
    Furumoto, Shozo
    Arai, Hiroyuki
    Yanai, Kazuhiko
    Kudo, Yukitsuka
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (11)
  • [3] Tau PET Imaging in Alzheimer’s Disease
    Nobuyuki Okamura
    Ryuichi Harada
    Shozo Furumoto
    Hiroyuki Arai
    Kazuhiko Yanai
    Yukitsuka Kudo
    Current Neurology and Neuroscience Reports, 2014, 14
  • [4] International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
    Mei Tian
    A. Cahid Civelek
    Ignasi Carrio
    Yasuyoshi Watanabe
    Keon Wook Kang
    Koji Murakami
    Valentina Garibotto
    John O. Prior
    Henryk Barthel
    Rui Zhou
    Haifeng Hou
    Xiaofeng Dou
    Chentao Jin
    Chuantao Zuo
    Hong Zhang
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 895 - 904
  • [5] International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer's disease
    Tian, Mei
    Civelek, A. Cahid
    Carrio, Ignasi
    Watanabe, Yasuyoshi
    Kang, Keon Wook
    Murakami, Koji
    Garibotto, Valentina
    Prior, John O.
    Barthel, Henryk
    Zhou, Rui
    Hou, Haifeng
    Dou, Xiaofeng
    Jin, Chentao
    Zuo, Chuantao
    Zhang, Hong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (03) : 895 - 904
  • [6] Novel PET probes for in vivo imaging of tau pathology in Alzheimer's disease
    Ito, S
    Okamura, N
    Katou, M
    Furumoto, S
    Akatsu, H
    Yamamoto, T
    Sawada, T
    Arai, H
    Kudo, Y
    Yanai, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 : 143P - 143P
  • [7] In vivo tau imaging in Alzheimer's disease
    Villemagne, Victor
    Furumoto, Shozo
    Fodero-Tavoletti, Michelle
    Mulligan, Rachel
    Hodges, John
    Kudo, Yukitsuka
    Masters, Colin
    Yanai, Kazuhiko
    Rowe, Christopher
    Okamura, Nobuyuki
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [8] IN VIVO TAU IMAGING IN ALZHEIMER'S DISEASE
    Villemagne, Victor L.
    Furumoto, Shozo
    Fodero-Tavoletti, Michelle T.
    Mulligan, Rachel S.
    Harada, Ryuichi
    Yanai, Kazuhiko
    Masters, Colin L.
    Kudo, Yukitsuka
    Rowe, Christopher C.
    Okamura, Nobuyuki
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 4 - 4
  • [9] Parametric imaging of tau load in Alzheimer's patients and controls using Flortaucipir
    Golla, S. S. V.
    Wolters, E.
    Timmers, T.
    Ossenkoppele, R.
    Groot, C.
    Verfaillie, S.
    Scheltens, P.
    van der Flier, W. M.
    Schwarte, L.
    Mintun, M. A.
    Devous, M.
    Schuit, R. C.
    Windhorst, A. D.
    Lammertsma, A. A.
    Boellaard, R.
    van Berckel, B. N. M.
    Yaqub, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S250 - S251
  • [10] PET imaging of tau pathology in Alzheimer's disease and tauopathies
    James, Olga G.
    Doraiswamy, P. Murali
    Borges-Neto, Salvador
    FRONTIERS IN NEUROLOGY, 2015, 6